Only one of four patients persisted with Novo Nordisk's (NVO) newer GLP-1 drugs, Wegovy or Ozempic, two years after taking the popular meds for weight loss, according to a Reuters' analysis of U ...
Most Patients Stop Using Wegovy, Ozempic for Weight Loss Within Two Years, Analysis Finds By Chad Terhune (Reuters) -Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or ...
Smokers with diabetes or obesity who take semaglutide (Ozempic/Wegovy) might reap an added benefit: Help in quitting ...
Researchers from Monell Chemical Senses Center have identified a specific population of neurons in the brain that could be ...
An Alzheimer’s study reported liraglutide appeared to slow cognitive decline compared to a placebo. Researchers plan more ...
Share on Pinterest GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound can affect people differently. BONNINSTUDIO/Stocksy United Misconceptions about the benefits and risks of GLP-1 drugs ...
As patients consider drugs like Wegovy, Ozempic, Zepbound and Mounjaro to treat obesity, experts say the choices are not so simple. By Gina Kolata Gina Kolata has reported on many facets of the ...
Research shows the drug can cut the risk of serious cardiovascular issues like heart attack and stroke in certain patients.
The review specifically excluded those taking GLP-1s for type 2 diabetes. 45% of patients were taking Ozempic or Wegovy, and the rest were on Novo's older GLP-1s, such as Saxenda or Victoza.
The next wave of obesity drugs could help people lose even more weight—and make some pharma companies a fortune.